Related Experiment Video
Updated: Aug 13, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
[Nonalcoholic fatty liver: does it have to be biopsed?]
Laura Rubbia-Brandt1, Antoine Hadengue
1Unité de pathologie gastro-intestinale et hépatique, Département de pathologie clinique, HUG, 1211 Genève 14.
Revue Medicale Suisse
|January 7, 2006
Summary
Obesity is rising globally, increasing liver disease risk. Current clinical tools lack certainty in predicting steatohepatitis or fibrosis in patients with fatty liver disease.
Area of Science:
- Hepatology
- Internal Medicine
- Public Health
Context:
- Rising global obesity rates are leading to an increased prevalence of liver diseases.
- Hepatic steatosis (fatty liver disease) is becoming a significant clinical challenge for healthcare providers.
- Identifying patients at high risk for steatohepatitis or fibrosis is crucial for timely intervention.
Purpose:
- To highlight the diagnostic challenges in managing patients with hepatic steatosis due to obesity.
- To underscore the limitations of current clinical scores and blood tests in predicting disease progression.
- To emphasize the need for validated criteria to identify at-risk individuals with fatty liver disease.
Summary:
- Obesity's epidemic nature is driving an increase in liver diseases, particularly hepatic steatosis.
- Medical professionals face challenges in assessing the risk of steatohepatitis or fibrosis in these patients.
- Existing clinical scores and blood tests lack sufficient validation for accurately predicting which patients require further investigation or intervention.
Impact:
- Improved diagnostic accuracy for hepatic steatosis progression.
- Enhanced patient stratification for liver disease management.
- Development of more reliable tools for identifying at-risk populations with fatty liver disease.
Related Concept Videos
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...